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Abstract
The chemical modification of structurally complex fermentation products, a process known as 
semisynthesis, has been an important tool for the discovery and manufacture of antibiotics for the 
treatment of various infectious diseases. However, many of the therapeutics obtained in this way 
are no longer efficacious, as bacterial resistance to many of these compounds has developed. In 
this manuscript, we describe a practical, fully synthetic route to macrolide antibiotics via the 
convergent assembly of simple chemical building blocks, with diverse structures not possible by 
traditional semisynthesis. More than 300 new macrolide antibiotic candidates, as well as the 
investigational drug solithromycin, were synthesized by our convergent approach. Evaluation of 
the novel compounds against a panel of pathogenic bacteria revealed many antibiotic candidates, 
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with efficacy against strains resistant to macrolides in current use. The chemistry we describe 
herein provides a platform for the discovery of new macrolide antibiotics and may also serve as a 
basis for their manufacture.
Introduction
Natural products have provided critical starting points for the development of a majority of 
the antibacterial drugs listed as essential medicines by the World Health Organization. 
During the period ~1940–1960, sometimes described as the golden age of antibiotics 
research, academic and industrial laboratories identified the natural products that went on to 
define many of the major classes of antibiotics in our modern day armamentarium.1 Few if 
any natural products prove to be optimal for safety, efficacy, or oral bioavailability in 
humans, however, for these were likely not evolutionary pressures for the microbes in which 
they developed. For six decades a primary tool by which new antibiotics have been 
discovered and manufactured is semisynthesis, or chemically modifying natural products 
derived from fermentation. Semisynthesis is inherently limited because it is challenging to 
selectively modify structurally complex natural products, and typically few positions of any 
given scaffold can be modified effectively.2,3 Macrolide antibiotics (macrocyclic lactones 
with one or more pendant glycosidic residues), which have proven to be safe and effective 
for use in treating human infectious diseases such as community-acquired bacterial 
pneumonia, gonorrhea, and others, provide a compelling case in point. Since the discovery 
of erythromycin from a Philippine soil sample in 1949,4 in spite of extraordinary efforts 
leading to fully synthetic5–8 and modified biosynthetic routes9–12 to macrolide antibiotics, 
all members of this class approved or in clinical development for use in humans have been 
manufactured by chemically modifying erythromycin (erythromycin itself is unstable in the 
stomach, and rearranges to form a product with gastrointestinal side-effects).13 Thus, 
azithromycin is prepared from erythromycin in four steps,14 clarithromycin requires six 
steps,15 and the advanced clinical candidate solithromycin is currently produced from 
erythromycin by a 16-step linear sequence (Figure 1).16,17 New macrolides are badly 
needed, for resistance to approved macrolide antibiotics such as clarithromycin and 
azithromycin is now widespread in both hospitals and the community.18–20 Here we present 
a practical, fully synthetic platform for the preparation of macrolide antibiotics, providing 
both a discovery engine for structurally novel antibiotic candidates that would be difficult or 
impossible to obtain from erythromycin, as well as a basis for their eventual manufacture. 
Using simple building blocks and a highly convergent assembly process, we have prepared 
more than 300 structurally diverse macrolide antibiotic candidates, as well as the approved 
drug telithromycin and the clinical candidate solithromycin. We have identified molecules 
with diverse macrocyclic scaffolds that exhibit potent activities against bacterial strains 
resistant to erythromycin, azithromycin, and other current antibiotics of different classes.
Synthesis of 14-membered azaketolides
To illustrate our approach to the synthesis of macrolide antibiotics we begin by detailing a 
route to new and highly active hybrid antibiotics, 14-membered azaketolides (Figure 2), and 
then show how the approach can be easily expanded to subsume many other active 
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macrolide scaffolds, with broad latitude for substitutional variation. Ketolides replace the 
C3-cladinose carbohydrate residue of erythromycin with a carbonyl group, a chemical 
modification that allows them to evade certain inducible forms of macrolide resistance,21,22 
whereas the azalide azithromycin incorporates a nitrogen atom within an expanded (15-
membered) macrolactone ring, features which have been proposed to impart favorable 
pharmacological properties, including increased efficacy against certain Gram-negative 
pathogens.23,24 The hybrid “azaketolides”, or macrolides that contain both a C3 carbonyl 
group and a nitrogen atom within the macrolactone ring, have been little explored; one such 
compound has been reported and was found to be essentially inactive.25 We were 
particularly interested in 14-membered azaketolides that would arise from formal 
replacement of the carbonyl group at position C9 of ketolides with an amino group, a 
transformation that would not be feasible by semisynthesis.
An overview is helpful as it emphasizes our synthetic strategy. Eight simple building blocks 
(1-8), two commercially available and six synthesized in 3–6-step sequences in 30–150-g 
amounts, are assembled in a highly convergent manner (Figure 2). As depicted, building 
blocks 1-3 are transformed by a seven-step sequence featuring two convergent coupling 
reactions to provide a key left-hand intermediate (15, an amine) in 57% yield, while building 
blocks 4–7 are transformed in a seven-step sequence featuring three convergent coupling 
reactions to form a key right-hand intermediate (22, a ketone) in 58% yield. The left- and 
right-hand intermediates are then joined in a highly stereoselective and efficient reductive 
coupling reaction (82% yield, d.r. > 20:1) that also serves to remove the benzoate protective 
group within the desosamine residue. The next step is the key macrocyclization reaction, for 
which we employ a method developed by Boeckman et al. in the context of their approaches 
toward the natural products diplodialide A (a 10-membered macrolactone), kromycin (a 14-
membered macrolactone), and ikarugamycin (a 17-membered macrolactam).26,27 We found 
that thermolysis of intermediate 23 (1 mM in chlorobenzene) at 132 °C afforded the 
macrolactone 24 in 78% yield (1-g scale). There are a number of notable features of this 
transformation, not least its efficacy and, as we will show, generality. Many pioneering 
efforts to synthesize macrolide antibiotics failed at the stage of macrocyclization; successful 
macrocyclizations were shown to require carefully designed, rigidifying protective group 
strategies.28 We believe that the success of the present cyclization (which we note occurs in 
the presence of a free secondary amine as well as another secondary alcohol) is attributable 
in part to the rigid structuring induced by the cyclic carbamate function on the left-hand side 
of the molecule, which we suspect favorably brings the putative acyl ketene function 
(produced from the dioxolenone function upon thermolysis) and the reactive secondary 
alcohol into proximity. A single operation then transforms the product of macrocyclization 
into a fully synthetic antibiotic candidate (25) while incorporating the final building block 
using Sharpless’ optimized conditions for azide-alkyne dipolar cycloaddition29 (8, 86% 
yield). This final step is by design a convergent coupling reaction, and permits optimal late-
stage diversification of a key side-chain residue that is known to occupy a novel pocket in 
the bacterial ribosome.30–34
Aspects of certain steps prior to the macrocyclization reaction merit brief discussion. The 
key aldol coupling reaction that unites building blocks 135 and 2,36 initiating the synthesis of 
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the left-half intermediate, involves new methodology that was developed specifically for the 
present purpose (though it proves to be a general transformation) and proceeds in 98% yield 
on a 33-g scale to form a single, crystalline diastereomer.36 In a subsequent step, which 
transforms the pseudoephenamine amide function into a methyl ketone in one operation, the 
pseudoephenamine auxiliary is recovered by a simple aqueous extraction procedure in 92% 
yield. The convergent coupling reaction that unites building blocks 4 and 5 to begin the 
construction of the right-half intermediate is based on a palladium-catalyzed ene reaction 
developed by Mikami and coworkers, and proceeds in 93% yield and 92% ee.37 Two 
convergent coupling reactions follow three linear functional group interconversions, the first 
coupling being a Mukaiyama38 aldol reaction (to incorporate building block 639) whose 
diastereoselectivity was observed to be dependent upon the reaction conditions. The 
conditions employed here (magnesium bromide etherate as Lewis acid, triethylamine as 
base, dichloromethane as solvent, and a reaction temperature of –78 °C) provided maximum 
selectivity (d.r. >20:1, 91% yield) for the desired syn-aldol product. The next convergent 
coupling reaction introduced the protected desosamine carbohydrate residue and for this 
purpose we employed the thioglycoside 7,40,41 a donor very similar to that employed by 
Woodward et al. in their synthesis of erythromycin.5 In the present case, we found that the 
use of a benzoyl group to shield the secondary alcohol on the glycosidic donor in lieu of 
methoxycarbonyl improved the yield and diastereoselectivity of the glycosidation reaction. 
The overall yield of the fully synthetic azaketolide antibiotic candidate 25 was 32% from 
initial building blocks 1 and 2 (a 10-step sequence) or 32% from initial building blocks 4 
and 5 (also a 10-step sequence).
Synthesis of 15-membered azaketolides
By design, the convergent building block strategy we employ enables rapid access to 
structurally related scaffolds; for example, synthesis of a 15-membered hybrid azaketolide 
scaffold comprising structural features of both the azalide antibiotic azithromycin and the 
ketolide clinical candidate solithromycin (Figure 3) required modification of just three of the 
eight building blocks that were used to assemble 14-membered azaketolides (Figure 2). The 
left-hand amine intermediate (15) was the same in both 14- and 15-membered azaketolide 
scaffold syntheses and thus construction of the 15-membered azaketolides simply required 
access to the homologated right-hand intermediate, aldehyde 35. Here, too, we employed a 
seven-step sequence (38% yield) featuring three convergent coupling reactions to assemble 
four simple building blocks. The first coupling, which unites building blocks 2642 and 
2743,44 to form the tertiary alcohol 29, emerged only after extensive experimentation, in 
which we discovered that incorporating the large tert-butyldiphenylsilyl protective group 
within component 27 was key to achieve high diastereoselectivity. After two subsequent 
functional group interconversions, building blocks 6 (as before) and 28 (the original glycosyl 
donor of Woodward et al.,5 which proved to be effective in this scaffold synthesis) were 
incorporated by successive convergent coupling reactions. Two linear steps then provided 
the right-hand intermediate, aldehyde 35. Reductive coupling of the left-hand amine (15) 
and the right-hand aldehyde (35) in the presence of sodium cyanoborohydride proceeded 
without detectable epimerization to afford the macrocyclization precursor 36 in 86% yield. 
Thermolysis of 36 at 132 °C in chlorobenzene then afforded the 15-membered macrolide 37 
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in 94% yield on a 1.9-g scale. Incorporation of the final building block (8, as before) and 
cleavage of the methoxycarbonyl protective group were achieved in a single, final step to 
provide the azaketolide antibiotic candidate 38. The overall yield of the fully synthetic 
macrolide 38 (FSM-20707 in Figure 5) was 43% from initial building blocks 1 and 2 (a 10-
step linear sequence) or 33% from initial building blocks 26 and 27 (also a 10-step linear 
sequence).
Synthesis of 14-membered ketolides
We next adapted our convergent assembly strategy to synthesize 14-membered ketolides, a 
class that includes the clinical candidate solithromycin as well as the approved drug 
telithromycin, with the goal of preparing diverse structural analogs. Toward this end we 
envisioned coupling of the same right-hand intermediate employed in the synthesis of 15-
membered azaketolides (aldehyde 35) with a Grignard reagent derived from 
hydromagnesiation of the acetylenic alcohol 42. Intermediate 42 was obtained in one step 
(14:1 d.r., 85% yield) by the addition of 1-lithiopropyne (39) to ketone 4035 in the presence 
of lithium (1S,2R)-1-phenyl-2-(pyrrolidin-1-yl)-1-propanolate.45 Hydromagnesiation of 42 
with cyclopentylmagnesium bromide and bis-cyclopentadienyltitanium dichloride46 
proceeded regioselectively to furnish a vinyl Grignard reagent that was captured in situ with 
aldehyde 35. The resulting diastereomeric mixture of allylic alcohols (obtained in 80% yield 
on a 3-g scale) was oxidized directly (Dess-Martin periodinane, 97%) and the α,β-
unsaturated ketone produced was desilylated (n-Bu4NF, 95%) to afford the keto alcohol 45. 
Macrocyclization, as before, then provided the 14-membered macrolactone 46 in 66% yield 
(1.7-g scale). Fluorination at position C2 proceeded in 85% yield.47 Transformation of the 
C12 tertiary alcohol within the latter intermediate (47) to the corresponding acyl imidazolide 
(Im2CO, DBU) and trapping with amine 49 then afforded fully synthetic solithromycin in 
one operation (87% yield, the methoxycarbonyl protective group was cleaved concomitantly 
under these conditions). The present route to solithromycin proceeds in 14 steps and 16% 
yield from building blocks 26 and 27, and differs from the semisynthetic route (16 steps 
from erythromycin, yields not reported16) in that the linker and its attached side-chain 
heterocycle are introduced in the final step of our synthesis and thus modification of these 
residues is quite facile, whereas the linker residue is introduced 6 steps prior to the 
penultimate step in the published semisynthetic route to solithromycin.16 We prepared a 
number of fully synthetic 14-membered ketolides by taking advantage of this feature of our 
synthesis to simultaneously vary the linker and side-chain heterocycle, and many of these 
products show potencies that are superior to solithromycin in microbiological assays (vide 
infra).
Construction of a Library of Macrolide Antibiotics
We prepared an initial library of >300 fully synthetic macrolide (FSM) antibiotic candidates 
by varying the building blocks in concert with modifying readily diversifiable elements (e.g., 
an azido group, an amino group, a β-keto lactone function, an allyl group, etc.) that we 
introduced into and around the macrolide ring, a powerful tactical combination. In addition 
to members of the three primary macrocyclic scaffolds discussed in detail above, we 
prepared a number of other unique scaffolds by modifying the principal coupling 
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components (left- and right-halves) and their modes of coupling using straightforward 
alternative chemical transformations (see Supplementary Information for a complete list of 
structures synthesized and Extended Data Figures 1–10 for exemplary schemes for their 
preparation). This strategy not only provided novel scaffolds to explore, but also permitted 
deep-seated variations of positions within these scaffolds, thus enabling access to molecules 
that could not be prepared using semisynthetic methods.
Microbiological Testing
To evaluate our fully synthetic macrolides for antibiotic activity we screened 305 of them 
against a panel of pathogens comprising standardized Gram-positive and Gram-negative 
strains (See Supplementary Information). For the most promising antibiotic candidates the 
panel was expanded to include bacteria with genetically characterized resistance 
mechanisms to erythromycin as well as other antibiotics. These include 3 different strains of 
S. aureus, two of them clinically isolated methicillin-resistant (MRSA) pathogens, a 
clinically isolated strain of S. pneumoniae with both ribosome-modifying methyltransferase 
(ermB) and efflux (mefA) genes, and finally a clinically isolated strain of E. faecalis with an 
ermB gene, a strain resistant to all approved macrolides as well as vancomycin (VRE) 
(Figure 5). The data show that a majority of compounds in the library exhibit demonstrable 
antibiotic activity. For example, 83% of compounds in the collection displayed an MIC ≤4 
μg/mL against wild-type S. pneumoniae, which is known to be highly susceptible to 
inhibition by macrolides (Supplementary Information). Among the most promising 
compounds (Figure 5) are represented variously 14-, 15-, and 16-membered azaketolide 
scaffolds (e.g., FSM-22391, FSM-20707, and FSM-21397, respectively), a 15-membered 
azacethromycin hybrid antibiotic (FSM-20919), and a number of fully synthetic 14-
membered ketolides (most notably, FSM-100573 and FSM-100563). The latter two 
substances display superior potencies relative to any macrolide in current clinical use in the 
following extremely challenging strains: an S. pneumoniae with both ermB and mefA genes 
(MIC’s ≤0.03 μg/mL), a VRE with an ermB gene (MIC’s 1 and 2 μg/mL, respectively), a 
MRSA with a constitutively-expressed erythromycin ribosome methyltransferase (c-erm) 
gene (MIC’s 16 μg/mL), and P. aeruginosa (MIC’s 16 and 32 μg/mL, respectively). Clearly, 
further work will be required to drive potencies in the latter two strains to clinically 
efficacious levels, but we believe that demonstration of even modest activity in these 
challenging strains by a macrolide is significant. It is interesting and encouraging to note 
that FSM-100573 also displays improved Gram-negative activity relative to many other 
macrolides; further advances in this regard would address an important area of unmet 
medical need.48
Conclusion
Employing as a design strategy the multiply convergent assembly of simple chemical 
building blocks we have developed a platform of unprecedented versatility for the discovery 
and practical synthesis of novel macrolide antibiotics. Varying the building blocks as well as 
(at a later stage) diversifiable elements incorporated within them permits an almost 
exponential expansion of variability within any given scaffold. In addition, our work shows 
that variant scaffolds can be obtained by straightforward perturbations of our generalized 
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assembly process. As with our earlier convergent synthesis of tetracycline antibiotics,49,50 
we anticipate that many thousands of novel macrolide structures can be prepared for 
evaluation as potential antibiotics using the present synthetic platform. In light of this, it 
seems logical to conclude that developing similar convergent routes to other naturally 
occurring antibiotic families may accelerate the discovery of new therapeutic agents for 
human infectious disease.
Extended Data
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Extended Data Figure 1 |. Synthesis of a C2-fluoro 14-membered azaketolide by a late-stage 
fluorination reaction.
Subjection of β-keto lactone 25 to potassium tert-butoxide (1.0 equiv) at –78 °C followed by 
N-fluorobenzenesulfonimide (1.0 equiv) afforded FSM-22391 in 43% yield.
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Extended Data Figure 2 |. Synthesis of a 15-membered azaketolide with a modified C2-
substituent.
Thermolysis of a β-keto tert-butyl ester substrate (55) proceeded at a lower temperature 
(80 °C) and afforded a 15-membered macrocycle without substitution at C2 (56). This 
macrocycle served as a nearly ideal intermediate for preparation of macrolides with diverse 
C2-substitutions. For example, an allyl group was introduced at C2 by treatment of 56 with 
sodium tert-butoxide (1.1 equiv) and allyl iodide (1.1 equiv) at –40 °C followed by warming 
the reaction solution to 23 °C. The product 57 (obtained in 62% yield) was then transformed 
to FSM-56156 in two steps (72% yield).
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Extended Data Figure 3 |. Synthesis of a 15-membered azacethromycin hybrid.
Macrolactone 63 was prepared from amine 60 and aldehyde 61 in two steps by a reductive 
amination–macrocyclization sequence. Treatment of 63 with paraformaldehyde (6.0 equiv) 
and acetic acid (10.0 equiv) furnished adduct 64 as a crystalline solid (84% yield). The 
imidazolidine group within 64 served to protect both the secondary amine and the cyclic 
carbamate functions, and permitted the introduction of a quinoline heterocycle via a Heck 
reaction. Methanolysis (TFA, CH3OH) cleaved the imidazolidine group, affording 
FSM-20919 (29%, two-step yield).
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Extended Data Figure 4 |. Synthesis of a 15-membered azaketolide with a modified C10-
substituent.
N-tert-butylsulfinyl imine 68 (prepared in five steps from amide 10) allowed for the 
stereocontrolled introduction of various C10-substituents. For example, addition of 
allylmagnesium bromide proceeded with >20:1 stereoselectively to furnish the adduct 
depicted; subsequent cleavage of the sulfinyl (HCl, CH3OH) and tert-butyldiphenylsilyl 
(Bu4NF) groups within the adduct then furnished left-hand intermediate 69 (81% yield). 
Amine 69 and aldehyde 35 were coupled by a reductive amination reaction (NaBH3CN, 60–
75% yield). The product (70) was then transformed to FSM-11044 in a three-step sequence 
that consisted of a macrocyclization reaction (72% yield), a methanolysis reaction 
(quantitative yield) and lastly a [3+2] dipolar cycloaddition reaction (92% yield).
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Extended Data Figure 5 |. Synthesis of a 15-membered azaketolide with a modified C13-
substituent.
Modification of position C13 was achieved by modification of a single component, in this 
case the ketone building block 74 depicted above. Reductive coupling of 78 and 35 united 
the left- and right-halves; subsequent thermal macrocyclization provided macrolactone 80. 
The allyl group within intermediate 80 was cleaved upon ozonolysis (O3, trifluoroacetic 
acid); reductive workup with sodium cyanoborohydride afforded alcohol 81. Subjection of 
81 to bis(2-methoxyethyl)aminosulfur trifluoride afforded the fluoroethyl-substituted 
macrocycle 82 (30%, two-step yield), which was transformed to FSM-11453 by a [3+2] 
dipolar cycloaddition reaction.
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Extended Data Figure 6 |. Synthesis of a 15-membered azaketolide with a modified desosamine 
sugar residue.
The 15-membered macrolactone 90 was synthesized using thioglycoside 84 and alkyne 89 as 
building blocks (in lieu of building blocks 28 and 8 used for the synthesis of 15-membered 
azaketolide FSM-20707). Treatment of 90 with tributyltin hydride (2.0 equiv), acetic acid 
(5.0 equiv), and tetrakis(triphenylphosphine)palladium (2 mol%) led to cleavage of the 
allyloxycarbonyl protective group, giving rise to amine 91 (92% yield). The latter 
intermediate has been transformed into a number of fully synthetic macrolides with modified 
desosamine sugar residues. For example, acylation of the primary amino group of 
intermediate 91 with pyridine-2-carbonyl chloride (2.0 equiv) in the presence of 
trimethylamine (3.0 equiv) followed by removal of the tert-butoxycarbonyl group afforded 
FSM-21887 (86%, two-step yield).
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Extended Data Figure 7 |. Synthesis of a 16-membered azaketolide.
Homologation of aldehyde 35 was achieved by a Wittig olefination reaction 
(CH3OCH3PPh3+Cl–, NaHMDS) followed by hydrolysis of the resulting enol ether to afford 
aldehyde 93 in 65% yield. Reductive coupling of amine 15 and aldehyde 93 furnished 
macrocyclization precursor 94 (73% yield). The 16-membered macrolactone 95 was 
obtained in 78% yield upon thermolysis of 94 (1mM, 132 °C). Two additional steps 
transformed 95 to the 16-membered azaketolide FSM-21397.
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Extended Data Figure 8 |. Synthesis of a 14-membered macrolide with a trans-olefin linkage.
Mesylate 98 was prepared in quantitative yield by treatment of alcohol 34 with 
methanesulfonyl chloride (1.50 equiv) and triethylamine (2.0 equiv). Displacement of 
mesylate 98 with sodium 1-phenyl-1H-tetrazole-5-thiolate (2.0 equiv) followed by oxidation 
of the resulting thioether with ammonium molybdate (0.20 equiv)–hydrogen peroxide (100 
equiv) afforded sulfone 100 in 70% yield. Aldehyde 101 and sulfone 100 were coupled in a 
Julia–Kocienski olefination reaction (NaHMDS, –78 → 23 °C) to provide a 4.8:1 mixture 
of E- and Z-olefin isomers. The E-isomer 102 was isolated and desilylated (Bu4NF, 79%). 
Thermolysis of the product 103 (1 mM, 132 °C) furnished the 14-membered macrocycle 104 
in 83% yield. 104 was then transformed to FSM-21079 in two additional steps 
(methanolysis and [3+2] dipolar cycloaddition).
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Extended Data Figure 9 |. Synthesis of a 15-membered macrolide with an amide linkage (C9-
N9a).
Oxidation of aldehyde 35 with sodium chlorite (10.0 equiv) in the presence of sodium 
dihydrogen phosphate (10.0 equiv) and 2-methyl-2-butene (100 equiv) afforded carboxylic 
acid 107 in 70% yield. Acid 107 and amine 15 were coupled in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (2.00 equiv) to provide amide 108. Macrocyclization of 
108 (1 mM, 132 °C) proceeded in 81% yield to afford macrolactam 109. Methanolysis and 
[3+2] dipolar cycloaddition then transformed 109 to FSM-21344 in two steps.
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Extended Data Figure 10 |. Synthesis of a 15-membered macrolide with an amide linkage (C10-
N9a).
Amine 112 was prepared in 70% yield by displacement of mesylate 98 with sodium azide 
followed by reduction of the resulting alkyl azide (H2, Pd). The coupling of amine 112 and 
acid 113 proceeded in 54% yield. The product, amide 114, was desilylated (Bu4NF, 80%) to 
afford the macrocyclization precursor 115. Thermal macrocyclization of 115 followed by 
cleavage of the methoxycarbonyl protective group afforded lactam 116 in 80% yield. 
Copper-catalyzed [3+2] dipolar cycloaddition then provided FSM-21473 in 64% yield.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We most gratefully acknowledge funding from Alastair and Celine Mactaggart, from a private family foundation, 
and from the Blavatnik Biomedical Accelerator Program at Harvard University. We thank NERCE (AI057159), W. 
Weiss (University of North Texas), and R. Alm and S. Lahiri (Macrolide Pharmaceuticals) for measuring MIC 
values, R. Alm and T. Dougherty (Harvard Medical School) for genetic characterization of a microbial resistance 
gene, and S.-L. Zheng (Harvard) for conducting X-Ray crystallographic analyses. I.B.S. acknowledges postdoctoral 
fellowship support from the National Institutes of Health (F32GM099233); Z.Z. is a Howard Hughes Medical 
Institute International Student Research fellow; A.L. acknowledges postdoctoral fellowship support from the Swiss 
National Science Foundation (PBGEPE2-139864) and the Novartis Foundation; D.T.H. is indebted to the Deutsche 
Forschungsgemeinschaft (DFG) for a postdoctoral fellowship (HO 5326/1-1); T.F. acknowledges Daiichi-Sankyo 
Co., Ltd. for financial support; Y.K. acknowledges support from the Engineering Promotion Fund of Gifu 
University.
Seiple et al. Page 17
Nature. Author manuscript; available in PMC 2019 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
References
1. Walsh C Antibiotics: Actions, Origins, Resistance. (American Society for Microbiology Press, 
2003).
2. Fischbach MA & Walsh CT Antibiotics for emerging pathogens. Science 325, 1089–1093 (2009). 
[PubMed: 19713519] 
3. Wright PM, Seiple IB & Myers AG The evolving role of chemical synthesis in antibacterial drug 
discovery. Angew. Chem. Int. Ed 53, 8840–8869 (2014).
4. Mcguire JM et al. Ilotycin, a new antibiotic. Antibiot. Chemother 2, 281–283 (1952).
5. Woodward RB et al. Asymmetric total synthesis of erythromycin. 3. Total synthesis of 
erythromycin. J. Am. Chem. Soc 103, 3215–3217 (1981).
6. Martin SF, Hida T, Kym PR, Loft M & Hodgson A The asymmetric synthesis of erythromycin B. J. 
Am. Chem. Soc 119, 3193–3194 (1997).
7. Kim HC & Kang SH Total synthesis of azithromycin. Angew. Chem 121, 1859–1861 (2009).
8. Andrade RB Total synthesis of desmethyl macrolide antibiotics. Synlett 26, 2199–2215 (2015).
9. Khosla C Harnessing the biosynthetic potential of modular polyketide synthases. Chem. Rev 97, 
2577–2590 (1997). [PubMed: 11851472] 
10. Cane DE, Walsh CT & Khosla C Harnessing the biosynthetic code: combinations, permutations, 
and mutations. Science 282, 63–68 (1998). [PubMed: 9756477] 
11. Marsden AFA et al. Engineering broader specificity into an antibiotic-producing polyketide 
synthase. Science 279, 199–202 (1998). [PubMed: 9422686] 
12. Park S et al. Genetic engineering of macrolide biosynthesis: past advances, current state, and future 
prospects. Appl. Microbiol. Biotechnol 85, 1227–1239 (2010). [PubMed: 19902203] 
13. Kurath P, Jones PH, Egan RS & Perun TJ Acid degradation of erythromycin A and erythromycin 
B. Experientia 27, 362–362 (1971). [PubMed: 5581079] 
14. Bright GM et al. Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-9a-
homoerythromycin A derivatives – a new class of macrolide antibiotics, the azalides. J. Antibiot 
41, 1029–1047 (1988). [PubMed: 3139603] 
15. Morimoto S, Takahashi Y, Watanabe Y & Omura S Chemical modification of erythromycins. 1. 
Synthesis and antibacterial activity of 6-O-methylerythromycins-A. J. Antibiot 37, 187–189 
(1984). [PubMed: 6706855] 
16. Fernandes PB Methods for treating gastrointestinal diseases. WO patent 2010/048599 (2010).
17. Putnam SD, Castanheira M, Moet GJ, Farrell DJ & Jones RN CEM-101, a novel fluoroketolide: 
antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. 
Diagn. Microbiol. Infect. Dis 66, 393–401 (2010). [PubMed: 20022192] 
18. Leclercq R Mechanisms of resistance to macrolides and lincosamides: nature of the resistance 
elements and their clinical implications. Clin. Infect. Dis 34, 482–492 (2002). [PubMed: 
11797175] 
19. Gaynor M & Mankin AS Macrolide antibiotics: binding site, mechanism of action, resistance. 
Curr. Top. Med. Chem 3, 949–960 (2003). [PubMed: 12678831] 
20. Subramanian SL, Ramu H & Mankin AS in Antibiotic Discovery and Development (eds 
Dougherty TJ & Pucci MJ) 455–484 (Springer US, 2012).
21. Bryskier A Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin. 
Microbiol. Infect. 6, 661–669 (2000). [PubMed: 11284926] 
22. Zhanel GG et al. The ketolides: a critical review. Drugs 62, 1771–1804 (2002). [PubMed: 
12149046] 
23. Retsema J et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-
ring macrolide with improved potency against Gram-negative organisms. Antimicrob. Agents 
Chemother 31, 1939–1947 (1987). [PubMed: 2449865] 
24. Girard AE et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new 
macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents 
Chemother 31, 1948–1954 (1987). [PubMed: 2830841] 
Seiple et al. Page 18
Nature. Author manuscript; available in PMC 2019 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Denis A & Agouridas C Synthesis of 6-O-methyl-azithromycin and its ketolide analog via 
Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime. Bioorg. Med. Chem. Lett 8, 
2427–2432 (1998). [PubMed: 9873555] 
26. Boeckman RK Jr. & Pruitt JR A new, highly efficient, selective methodology for formation of 
medium-ring and macrocyclic lactones via intramolecular ketene trapping: an application to a 
convergent synthesis of (–)-kromycin. J. Am. Chem. Soc. 111, 8286–8288 (1989).
27. Boeckman RK Jr. & Perni RB Studies directed toward the synthesis of naturally occurring 
acyltetramic acids. 2. Preparation of the macrocyclic subunit of ikarugamycin. J. Org. Chem 51, 
5486–5489 (1986).
28. Woodward RB et al. Asymmetric total synthesis of erythromycin. 2. Synthesis of an erythronolide 
A lactone system. J. Am. Chem. Soc 103, 3213–3215 (1981).
29. Rostovtsev VV, Green LG, Fokin VV & Sharpless KB A stepwise Huisgen cycloaddition process: 
copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew. Chem 114, 
2708–2711 (2002).
30. Berisio R et al. Structural insight into the antibiotic action of telithromycin against resistant 
mutants. J. Bacteriol 185, 4276–4279 (2003). [PubMed: 12837804] 
31. Tu D, Blaha G, Moore PB & Steitz TA Structures of MLSBK antibiotics bound to mutated large 
ribosomal subunits provide a structural explanation for resistance. Cell 121, 257–270 (2005). 
[PubMed: 15851032] 
32. Llano-Sotelo B et al. Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits 
protein synthesis. Antimicrob. Agents Chemother 54, 4961–4970 (2010). [PubMed: 20855725] 
33. Bulkley D, Innis CA, Blaha G & Steitz TA Revisiting the structures of several antibiotics bound to 
the bacterial ribosome. Proc. Natl. Acad. Sci. U.S.A 107, 17158–17163 (2010). [PubMed: 
20876130] 
34. Eyal Z et al. Structural insights into species-specific features of the ribosome from the pathogen 
Staphylococcus aureus. Proc. Natl. Acad. Sci. U.S.A 112, E5805–E5814 (2015). [PubMed: 
26464510] 
35. Seiple IB, Hog DT & Myers AG Practical protocols for the preparation of highly enantioenriched 
silyl ethers of (R)-3-hydroxypentan-2-one, building blocks for the synthesis of macrolide 
antibiotics. Synlett 27, 57–60 (2016).
36. Seiple IB, Mercer JAM, Sussman RJ, Zhang Z & Myers AG Stereocontrolled synthesis of syn-β-
hydroxy-α-amino acids by direct aldolization of pseudoephenamine glycinamide. Angew. Chem. 
Int. Ed 53, 4642–4647 (2014).
37. Mikami K, Kawakami Y, Akiyama K & Aikawa K Enantioselective catalysis of ketoester-ene 
reaction of silyl enol ether to construct quaternary carbons by chiral dicationic palladium(II) 
complexes. J. Am. Chem. Soc 129, 12950–12951 (2007). [PubMed: 17918947] 
38. Mukaiyama T, Narasaka K & Banno K New aldol type reaction. Chem. Lett 2, 1011–1014 (1973).
39. Zhang Z, Kitamura Y & Myers AG An efficient directed Claisen reaction allows for rapid 
construction of 5,6-disubstituted 1,3-dioxin-4-ones. Synthesis 47, 2709–2712 (2015).
40. Hauske JR & Schulte GR Desosamino derivatives of macrolides as immunosuppressants and 
antifungal agents. WO patent 1993018042 (1993).
41. Zhang Z, Fukuzaki T & Myers AG Synthesis of D-desosamine and analogs by rapid assembly of 3-
amino sugars. Angew. Chem. Int. Ed 55, 523–527 (2016).
42. Leyes AE & Poulter CD Synthesis of (R)-[2–2H]isopentenyl diphosphate and determination of its 
enantiopurity by 2H NMR spectroscopy in a lyotropic medium. Org. Lett 1, 1067–1070 (1999). 
[PubMed: 10825959] 
43. Tan Z & Negishi E-i. An efficient and general method for the synthesis of α,ω-difunctional 
reduced polypropionates by Zr-catalyzed asymmetric carboalumination: synthesis of the 
scyphostatin side shain. Angew. Chem. Int. Ed 43, 2911–2914 (2004).
44. Santaniello E, Ferraboschi P & Grisenti P An efficient chemo-enzymatic approach to the 
enantioselective synthesis of 2-methyl-1,3-propanediol derivatives. Tetrahedron Lett. 31, 5657–
5660 (1990).
Seiple et al. Page 19
Nature. Author manuscript; available in PMC 2019 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
45. Thompson AS, Corley EG, Huntington MF & Grabowski EJJ Use of an ephedrine alkoxide to 
mediate enantioselective addition of an acetylide to a prochiral ketone: asymmetric synthesis of the 
reverse transcriptase inhibitor L-743,726. Tetrahedron Lett. 36, 8937–8940 (1995).
46. Sato F, Ishikawa H, Watanabe H, Miyake T & Sato M Specific hydromagnesiation of prop-2-ynylic 
alcohols. A simple and specific route to terpenoids. J. Chem. Soc., Chem. Commun, 718–720 
(1981).
47. Ashley G et al. Ketolide antibacterials. US patent 6590083 (2003).
48. CDC’s Antibiotic Resistance Threats in the United States: http://www.cdc.gov/drugresistance/
threat-report-2013/pdf/ar-threats-2013-508.pdf (2013).
49. Charest MG, Lerner CD, Brubaker JD, Siegel DR & Myers AG A convergent enantioselective 
route to structurally diverse 6-deoxytetracycline antibiotics. Science 308, 395–398 (2005). 
[PubMed: 15831754] 
50. Liu F & Myers AG Development of a platform for the discovery and practical synthesis of new 
tetracycline antibiotics. Curr. Opin. Chem. Biol, under review (2015).
Seiple et al. Page 20
Nature. Author manuscript; available in PMC 2019 May 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1 |. Summary of macrolide antibiotic development by semisynthesis.
To date, all macrolide antibiotics are produced by chemical modification (semisynthesis) of 
erythromycin, a natural product produced on ton-scale by fermentation. Depicted are the 
approved semisynthetic macrolide antibiotics clarithromycin, azithromycin, and 
telithromycin along with the dates of their FDA approval and the number of steps for their 
synthesis from erythromycin. The previous ketolide clinical candidate cethromycin and the 
current clinical candidate solithromycin are also depicted. It is evident that increasingly 
lengthy sequences are being employed in macrolide discovery efforts.
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Figure 2 |. A convergent, fully synthetic route to the 14-membered azaketolide 25.
a, Graphical representation of the convergent synthesis of azaketolide 25 from eight variable 
building blocks (represented by colored spheres). Downward, Y-shaped arrows signify 
convergent coupling reactions. b, Synthesis of azaketolide 25, reagents and conditions 
(subscripts L and R indicate left and right halves, respectively): (aL) LiHMDS, LiCl, 98%; 
(bL) EtiPr2N, COCl2; (cL) iPrMgCl, CH3Li, 76% over 2 steps, 92% of recovered (R,R)-
pseudoephenamine; (dL) NaHMDS; (eL) NaN3, 88% over 2 steps; (fL) NH3, Ti(OiPr)4, 
NaBH4, 95%; (gL) Bu4NF, 92%; (aR) Pd[(S)-SegPhos]Cl2, AgSbF6, 93%, 92% ee; (bR) 
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ethylene glycol, PPTS, 92%; (cR) KH, MeI, 97%; (dR) (iBu)2AlH, 96%; (eR) Et3N, 
MgBr2•OEt2, 91%; (fR) AgOTf, 81%, 16:1 β:α; (gR) HCl, 100%; (h) NaCNBH3, 82%; (i) 
132 °C, 1 mM, PhCl, 78%; (j) CuSO4, sodium L-ascorbate, 86%.
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Figure 3 |. A convergent, fully synthetic route to the 15-membered azaketolide 38.
a, Graphical representation of the convergent synthesis of azaketolide 38 from eight variable 
building blocks (represented by colored spheres). Downward, Y-shaped arrows signify 
convergent coupling reactions. b, Synthesis of azaketolide 38, reagents and conditions 
(subscripts L and R indicate left and right halves, respectively): (aL) LiHMDS, LiCl, 98%; 
(bL) EtiPr2N, COCl2; (cL) iPrMgCl, CH3Li, 76% over 2 steps, 92% of recovered (R,R)-
pseudoephenamine; (dL) NaHMDS; (eL) NaN3, 88% over 2 steps; (fL) NH3, Ti(OiPr)4, 
NaBH4, 95%; (gL) Bu4NF, 92%; (aR) tBuLi, MgBr2, 81%; (bR) KH, MeI, 99%; (cR) H5IO6, 
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99%; (dR) ZnCl2, 91%; (eR) AgOTf, 70%; (fR) HF (aq); (gR) Dess–Martin periodinane, 87% 
over 2 steps; (h) NaCNBH3, 86%; (i) 132 °C, 1 mM, PhCl, 94%; (j) CuSO4, sodium L-
ascorbate, 93%.
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Figure 4 |. A convergent, fully synthetic route to solithromycin.
a, Graphical representation of the convergent synthesis of solithromycin, which was 
previously only accessible by semisynthesis. This route has been adapted for the synthesis of 
>30 novel ketolide antibiotic candidates, as well as the FDA-approved ketolide 
telithromycin. Downward, Y-shaped arrows signify convergent coupling reactions. b, 
Synthesis of solithromycin, reagents and conditions (subscripts L and R indicate left and 
right portions, respectively): (aL) lithium (1S,2R)-1-phenyl-2-(pyrrolidin-1-yl)-1-
propanolate, 85%; (bL) CuSO4, sodium L-ascorbate, 95%; (aR) tBuLi, MgBr2, 81%; (bR) 
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KH, MeI, 99%; (cR) H5IO6, 99%; (dR) ZnCl2, 91%; (eR) AgOTf, 70%; (fR) HF (aq), 95%; 
(gR) Dess–Martin periodinane, 92%; (h) Cp2TiCl2, cyclopentylmagnesium bromide, 80%; 
(i) Dess–Martin periodinane, 97%; (j) Bu4NF, 95%; (k) 132 °C, 0.5 mM, PhCl, 66%; (l) 
KOtBu, FN(SO2Ph)2, 85%; (m) Im2CO, DBU; (n) imidazole hydrochloride, 60 °C, 87% 
over 2 steps.
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Figure 5 |. Minimum inhibitory concentrations (μg/mL) for selected analogs against 9 Gram-
positive and 5 Gram-negative microorganisms.
iErmA – inducible erythromycin ribosome methyltransferase A; cErmA – constitutive 
erythromycin ribosome methyltransferase A; MsrA – macrolide streptogramin resistance 
efflux pump A; MefA – macrolide efflux protein A; ErmB – erythromycin ribosome 
methyltransferase B; Erythro – erythromycin; Azithro – azithromycin; Telithro – 
telithromycin; Solithro – solithromycin.
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